December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Seres Therapeutics, Inc. - Common Stock (NQ:MCRB)

14.73 -0.55 (-3.60%)
Streaming Delayed Price Updated: 3:42 PM EST, Jan 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Seres Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Mid-Afternoon Market Update: Dow Rises Over 50 Points; ImmunoPrecise Antibodies Shares Spike Higher ↗
Toward the end of trading Thursday, the Dow traded up 0.16% to 34,853.89 while the NASDAQ rose 0.38% to 14,687.85. The S&P also rose, gaining 0.20% to 4,367.55. The U.S. has... 
Via Benzinga
Topics Stocks
News headline image
38 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) shares climbed 129.7% to $12.75 after the company announced new results from its TATX-03 PolyTope Therapy, demonstrating... 
Via Benzinga
News headline image
Stocks Flat as Nasdaq Tries For 3 Straight ↗
A surprise jump in jobless claims is weighing on investor sentiment midday. The Dow Jones Industrial Average is down 34 points, while the S&P 500 Index is trading near breakeven. 
Via Talk Markets
Topics Stocks
News headline image
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge ↗
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
News headline image
Mid-Day Market Update: Crude Oil Up 1.5%; Seres Therapeutics Shares Plunge ↗
Midway through trading Thursday, the Dow traded down 0.08% to 34,768.64 while the NASDAQ rose 0.10% to 14,646.39. The S&P also fell, dropping 0.02% to 4,357.70. The U.S. has... 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Gainers NRX Pharmaceuticals (NASDAQ:NRXP) stock increased by 53.01% to $15.47 during Thursday's regular session. As of 12:30 EST, this security is trading at a volume... 
Via Benzinga
News headline image
Why Seres Therapeutics Stock Is Crashing Today ↗
The company reported disappointing results from a phase 2b clinical study. 
Via The Motley Fool
News headline image
Mid-Morning Market Update: Markets Mostly Lower; AT&T Beats Q2 Estimates ↗
Following the market opening Thursday, the Dow traded down 0.24% to 34,715.42 while the NASDAQ rose 0.13% to 14,651.19. The S&P also fell, dropping 0.08% to 4,355.29. The U.S... 
Via Benzinga
Topics Stocks
News headline image
The Daily Biotech Pulse: FDA Nod For Merck-Eisai, Seres' Ulcerative Colitis Drug Flunks Midstage Study, Pfizer To Invest In Arvinas, AbSci IPO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 21) Biohaven Pharmaceutical... 
Via Benzinga
News headline image
Seres Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2b Study of SER-287 to Treat Mild-to-Moderate Ulcerative Colitis
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics Stock Plunges As Ulcerative Colitis Candidate Disappoints In Mid-Stage Study ↗
Seres Therapeutics Inc (NASDAQ: MCRB) has announced topline results from the Phase 2b ECO-RESET study evaluating SER-287 in patients with mild-to-moderate ulcerative colitis... 
Via Benzinga
News headline image
Seres Therapeutics Announces Topline Results for SER-287 Phase 2b Study in Mild-to-Moderate Ulcerative Colitis
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Nestlé Bets $525M On Seres Therapeutics Microbiome Drug For Infectious Diseases ↗
Seres Therapeutics Inc (NASDAQ: MCRB) has inked a $525-million deal with Nestlé Health Science to commercialize SER-109 if it can win FDA approval. SER-109 is an... 
Via Benzinga
News headline image
Seres Therapeutics, Nestlé Health Science Announce SER-109 Co-Commercialization License Agreement
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics to Present at JMP Securities Life Sciences Conference
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics to Host Virtual Investor Event on June 21, 2021
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics Presents Research from its Early-Stage Microbiome Therapeutic Oncology Programs at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics Gets FDA Green Signal to Start SER-155 Human Trials ↗
The FDA has signed off Seres Therapeutics Inc's (NASDAQ: MCRB) Investigational New Drug (IND) application for SER-155 to initiate Phase 1 trial. SER-155 is a... 
Via Benzinga
News headline image
Seres Therapeutics Announces FDA Clearance of IND for SER-155, an Investigational Microbiome Therapeutic for the Prevention of Antibiotic-Resistant Bacterial Infections and Graft-versus-Host Disease (GvHD)
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics to Present at Upcoming Virtual Investor Conferences
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics Presents Data Across its Broad Microbiome Pipeline Including New 24-Week Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection at Digestive Disease Week 2021
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics Announces David Arkowitz to Join as Executive Vice President, Chief Financial Officer and Head of Business Development
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics to Present Clinical Research on the Microbiome’s Impact on Allogeneic Hematopoietic Stem Cell Transplantation and Cancer Immunotherapy at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics to Present at RBC Capital Markets 2021 Global Healthcare Conference
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Gainers Applied DNA Sciences (NASDAQ:APDN) shares rose 27.71% to $7.42 during Tuesday's regular session. Trading volume for Applied DNA Sciences's stock is 7.2... 
Via Benzinga
News headline image
Seres Therapeutics to Present Key Data on Investigational Microbiome Therapeutics for Recurrent C. difficile Infection and Ulcerative Colitis at the Digestive Disease Week (DDW) Annual Meeting
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 3) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
News headline image
Seres Therapeutics: Q1 Earnings Insights ↗
Shares of Seres Therapeutics (NASDAQ:MCRB) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share were down 39.29% year over year to ($0... 
Via Benzinga
News headline image
Seres Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Earnings Scheduled For May 4, 2021 ↗
Companies Reporting Before The Bell • Lancaster Colony (NASDAQ:LANC) is likely to report quarterly earnings at $1.24 per share on revenue of $340.02 million. •... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.